Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term efficacy and safety of Artemisia annua allergen sublingual immunotherapy drops in adult allergic rhinitis
ChiCTR2200060121Phase 4Completed
- Sponsor
- Beijing Tongren Hospital
- Start
- Mar 2022
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of artemisia annua pollen allergen extract in allergic rhinitis (AR) and allergic conjunctivitis (AC), sponsored by Beijing Tongren Hospital. Primary endpoint: daily average combined scores of rhinitis symptoms and medication in pollen peak period. Started Mar 2022; status: completed.
02
Drugs
artemisia annua pollen allergen extract
03
Conditions
allergic rhinitis (AR)allergic conjunctivitis (AC)
Beyond the preview
Go deeper on ChiCTR2200060121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060121.